Back to Resource Hub White paper

Mixing Modes of PRO Data Collection in Trials Affected by COVID-19

Many clinical studies rely on site-based patient-reported outcome measures (PROMs), but the sudden requirement for social distancing and other restrictions because of the recent COVID-19 crisis necessitated adaptations to data collection strategies.

Learn from eCOA and ePRO expert, Dr. Bill Byrom, how mixing modes of PRO data collection allows sponsors to continue conducting clinical trials during the pandemic. He also details why sponsors and sites need to consider the following:

  • Existing equivalence data
  • Identifying data captured by alternative methods
  • Maintaining data integrity

Similar posts

Looking for more insights? Explore related resources.

GUIDE

Why Capture PRO Data in Early-Phase Oncology Trials

GET THE GUIDE
WHITE PAPER

Overcoming Data Quality Challenges During COVID-19

READ THE PAPER
WHITE PAPER

Takeaways and Perspectives: FDA Draft Guidance on DCTs

READ THE PAPER

Get notified on new marketing insights

Here mention the benefits of subscribing